Prentoe, Jannick http://orcid.org/0000-0003-2203-9478
Janitzek, Christoph M.
Velázquez-Moctezuma, Rodrigo http://orcid.org/0000-0001-9865-152X
Soerensen, Andreas http://orcid.org/0000-0003-2397-9568
Jørgensen, Thomas
Clemmensen, Stine
Soroka, Vladislav
Thrane, Susan
Theander, Thor
Nielsen, Morten A. http://orcid.org/0000-0003-2668-4992
Salanti, Ali
Bukh, Jens http://orcid.org/0000-0002-7815-4806
Sander, Adam F. http://orcid.org/0000-0002-8782-7830
Funding for this research was provided by:
Lundbeckfonden (R335-2019-2052, R303-2018-3396)
EC | Eurostars (E11019, E11019, E11019)
Sundhed og Sygdom, Det Frie Forskningsråd (6110-00177B, 4004-00598, 6110-00177B)
Kræftens Bekæmpelse (R204-A12639)
Novo Nordisk Fonden (NNF17OC0029372, NNF19OC0054518)
Article History
Received: 4 January 2022
Accepted: 31 October 2022
First Online: 15 November 2022
Competing interests
: C.M.J., S.T., T.T., M.A.N., A.S., and A.F.S. are co-inventors on a patent application on the used AP205 cVLP vaccine technology (WO2016112921 A1) licensed to AdaptVac. A.F.S. is currently partially employed by AdaptVac. The rest of the authors declare no competing interests.
: All mouse studies included in this paper were planned and conducted according to the Federation of European Laboratory Animal Science Associations (FELASA) Guidelines and were approved by the Danish Animal Experiments Inspectorate (Approval number: 2013-15-2934-00902/BES).